Foreign-Trade Zone (FTZ) 7-Mayaguez, Puerto Rico, Notification of Proposed Production Activity, Bristol-Myers Squibb Holdings Pharma, Ltd. (Pharmaceuticals), Manati, Puerto Rico

• Citation: 84 FR 23759
• Record Number: 2019-10805
• Published date: 23 May 2019
• Section: Notices
• Court: Foreign-trade Zones Board

Federal Register, Volume 84 Issue 100 (Thursday, May 23, 2019)

[Federal Register Volume 84, Number 100 (Thursday, May 23, 2019)]
                [Notices]
                [Pages 23759-23760]
                From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
                [FR Doc No: 2019-10805]
                =======================================================================
                -----------------------------------------------------------------------
                DEPARTMENT OF COMMERCE
                Foreign-Trade Zones Board
                [B-36-2019]
                Foreign-Trade Zone (FTZ) 7--Mayaguez, Puerto Rico, Notification
                of Proposed Production Activity, Bristol-Myers Squibb Holdings Pharma,
                Ltd. (Pharmaceuticals), Manati, Puerto Rico
                 Bristol-Myers Squibb Holdings Pharma, Ltd. (BMS) submitted a
                notification of proposed production activity to the FTZ Board for its
                facility in Manati, Puerto Rico. The notification conforming to the
                requirements of the regulations of the FTZ Board (15 CFR 400.22) was
                received on May 13, 2019.
                 BMS already has authority to produce certain pharmaceutical
                products within Subzone 7J. The current request would add finished
                products and a foreign status material/component to the scope of
                authority. Pursuant to 15 CFR 400.14(b), additional FTZ authority would
                be limited to the specific foreign-status material/component and
                specific finished products described in the submitted notification (as
                described below) and subsequently authorized by the FTZ Board.
                [[Page 23760]]
                 Production under FTZ procedures could exempt BMS from customs duty
                payments on the foreign-status materials/components used in export
                production. On its domestic sales, for the foreign-status material/
                component noted below and in the existing scope of authority, BMS would
                be able to choose the duty rates during customs entry procedures that
                apply to pegbelfermin in measured and finished dosages (duty-free). BMS
                would be able to avoid duty on foreign-status components which become
                scrap/waste. Customs duties also could possibly be deferred or reduced
                on foreign-status production equipment.
                 The material/component sourced from abroad is pegbelfermin--active
                pharmaceutical ingredient (duty-free).
                 Public comment is invited from interested parties. Submissions
                shall be addressed to the Board's Executive Secretary and sent to:
                [email protected]. The closing period for their receipt is July 2, 2019.
                 A copy of the notification will be available for public inspection
                in the ``Reading Room'' section of the Board's website, which is
                accessible via www.trade.gov/ftz.
                 For further information, contact Christopher Wedderburn at
                [email protected] or (202) 482-1963.
                 Dated: May 17, 2019.
                Andrew McGilvray,
                Executive Secretary.
                [FR Doc. 2019-10805 Filed 5-22-19; 8:45 am]
                BILLING CODE 3510-DS-P